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Infections produced in adult mice by the neurotropic Armstrong strain of lymphocytic
choriomeningitis (LCM)' virus can result in either of two contrasting outcomes, each of
which depends on the route of virus administration . Inoculated intracerebrally (i.c .), any
dose of infectious virus replicates predominantly in neural membranes, with little or no
extension to parenchymal cells of the central nervous system (CNS) and with minimal
involvement of extraneural tissues (1, 2) . Although the infection is noncytopathic, an
acute uniformly fatal CNS disease develops as a direct result of virus-induced immune-
mediated damage to infected cells of theleptomeninges, choroid plexus, andependyma (1,
3) . Convincing evidence for the immunopathological nature of LCM comes from our
previous studies in which immunosuppression with cyclophosphamide (CY) after cerebral
infection was shown to prevent thedevelopment of CNS disease and to subsequently lead
to the development of a chronic asymptomatic virus-carrier state (l, 4) . In contrast, mice
given LCM virus by an extraneural route develop a self-limiting subclinical infection
confined to extraneural tissues and which eventually confers a solid protective immunity
to a second challenge of virus given i.c . (5) . However, under appropriate conditions,
splenic lymphocytes from suchimmunized mice, when adoptively transferred to syngeneic
CY-induced virus-carrier mice, regularly mediate acute lethal CNS disease which,
histologically and clinically, is typical of classicalLCM (1, 3) . As first shown by Cole et al .
(6), both CNS disease and virus clearance mediated by exogenous immune lymphoid cells
requires the participation of thymus-derived (T) lymphocytes . Depletion of this popula-
tion with anti-B serum and complement (C) completely abrogates the ability of the
transferred cells to elicit LCM but not their capacity to produce virus-specific antibody .
These results and the fact that column-purified immune donor T lymphocytes can
effectively mediate virus clearance in carrier recipients without accompanying antibody
production (M . Volkert, personal communication) arguestrongly against a significant role
for antibody in producing acute disease .
The expression of LCM virus-specific cellular immune reactivity can also be demon-
strated in vitro. Splenic lymphocytes, obtained from peripherally infected adult mice,
*Supported in part by U. S. Public Health Service grants NS 11286 and RR 05445 and a
Brown-Hazen Grant from the Research Corporation .
t Recipient of U . S . Public Health Service Research Career Development Award NS 46242 .
' Abbreviations used in this paper : AT x BM, mice thymectomized as adults, lethally irradiated,
and reconstituted with bone marrow; CY, cyclophosphamide ; i .c ., intracerebral or intracerebrally ;
l'l'I JUDR, J5-"I J2'-deoxyuridine ; LCM, lymphocytic choriomeningitis .
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have the ability to specifically lyse cultures of virus-infected mouse fibroblasts (7). Such
lytic activity, as measured by "Cr release, has been shown to be present at high levels
mainly during the 2nd wk postinf'ection, and also to be ablated by treatment with anti-B
serum and C (7, 8) .
From previous studies (9, 10), we had noted that there was a poor correlation
between the ability of immune donor splenic lymphocytes to produce LCM in
CY-induced virus-carrier mice and their lytic capacity in vitro. In fact, mediation
of disease in the majority of any group of carrier recipients was possible only
when spleens were obtained from donors which had been immunized about 3 wk
previously, well beyond the time at which they contained maximal cytolytic
activity . These initial observations led us to postulate the existence of two
populations of T lymphocytes differing in their functional capabilities and
generated at different times during virus-specific immune induction (9). We now
present the results of studies which both confirm and extend these observations
and which discriminate between memory and effector T lymphocytes on the
basis of their respective roles in either protecting against or mediating fatal CNS
disease. The generation of a cell population containing the potential to become
cytolytically active or "killer" T lymphocytes may be the final common pathway
to both outcomes ; however each outcome is determined by the relative kinetics of
virus replication and immune induction.
Materials and Methods
Mice. Male BALB/c mice, aged 6-10 wk, (Flow Laboratories, Inc., Dublin, Va., or Carworth
Farms, Nutley, N. J.) or C3H x C57BI F, mice (provided by Dr. Norman Morrison, The Johns
Hopkins University), were employed in all adoptive transfer experiments. C3H x C57BL F, mice
were either thymectomized at 4 wk of age, lethally irradiated and reconstituted with syngeneic bone
marrow (AT x BM), or unmanipulated. AT x BM mice were used between 3 and 4 wk after marrow
reconstitution. Adult Swiss Webster (ICR) mice (Microbiological Associates, Walkersville, Md.) were
used forvirus titrations.
Virus.
￿
TheArmstrong E-350strain of LCMvirus (ATCCVRno . 134) was used throughout. Stock
virus wasprepared by i.e. inoculation of adultICR mice, and brains were harvested6days later(4). A
clarified 20% homogenate in phosphate-buffered saline (PBS) was stored at -70°C. This preparation
had an adult mouse i.e. titer of 106 (LDSO)/0.03 ml. In some experiments, control animals were
inoculated with dilutions of normal brain homogenate prepared in an identical fashion.
Virus Titrations . Brains from saline-perfused COz-anesthetized mice were removed, homoge-
nized, and prepared as clarified 20% suspensions in PBS. Decimal dilutionswere inoculated i.e. into
adult ICR mice. Virus titers were calculated by the Karber method (11) and expressed as the
LD,J0.03 g.
Cells for Adoptive Immunization.
￿
Immune donors received one or more intraperitoneal (i .p.)
doses of 1,000 LDso of virus. Immune or normal donor spleen cell suspensions were prepared by
teasing through a stainless steel mesh into a sterile Petri dish containing Eagle's minimum essential
medium (MEM) with penicillin (100 A/ml) and streptomycin (0.1 mg/ml) . After removing rapidly
settling aggregates, thecellswere washed once in MEM, and adjusted to a concentration of 10 or 100
x 106 nucleated cells/ml. About 95% of these cells were viable as determined by trypan blue
exclusion. All lymphoid cell transfers consistedof 1.0-ml voladministered by thei.p. route.
CY-Induced LCM Virus Carriers. Detailed procedures have been previously described (4). In
brief, 3 days after the i .e. inoculation of 6- to 8-wk old BALB/c mice with 10' LDso of LCM virus, a
single i.p. dose of CY (150 mg/kg of body weight) was administered. This procedure leads to the
development of a permanent virus-carrier state in about 90% of infected immunosuppressed mice.
Virus carriers were adoptively immunized between 10 and 15 days after virus inoculation.
Cytotoxicity Assay.
￿
The method is essentially that described in a previous report (7). 3 days after86)8
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inoculating 60% confluent monolayers of BALB 3T3 cells with LCM virus at a multiplicity of
infection of about 10 mouse LD 5dcell, the infected cultures and companion uninfected cultures were
trypsinized, labeled with "Cr (sodium chromate, New England Nuclear, Boston, Mass .), and
washed . Aliquots were seeded into four-chambered tissue culture slides (Lab-Tek Products, Div.
Miles Laboratories Inc. Westmont, Ill.) and after adhering, the proportion of cells containing
virus-specific antigens was determined by immunofluorescent staining . Only infected preparations
containing 90% or more fluorescing cells were used in cytotoxicity assays . Target cells were
co-cultivated with splenic lymphocytesfrom either normal or immune mice as mixtures standardized
to contain 1 x 10' viable lymphocytes and 1 x 10 5 target cells. After incubation for 18 h at 36°C in air
containing 5% CO ., the mixtures were centrifuged and the cell-free supernates counted for "Cr.
The percentage of specific cell lysis was calculated by subtracting from the percentage of $'Cr
released in the presence of immune splenic lymphocytes, that percentage of label released in the
presence of normal lymphocytes. (Percentage cytolysis = counts in cell-free supernates x 100 - total
counts .)
DNA Synthesis in Spleens .
￿
As an indicator of lymphoid cell proliferation in donor mice after
LCM virus immunization, the rate of DNA synthesis in their spleens was measured . From
preliminary experiments it was determined that essentially identical DNA-synthetic response curves
were generated using either tritiated thymidine or [5-"'1]-2-'-deoxyuridine Q"SIJUDR, Amersham/
Searle Corp ., Arlington Heights, Ill.) . Therefore, the latter isotopewas employed routinely because of
the ease with which it could be measured . At various intervals, groups of 3-4 immunized mice, and
control animals inoculated i.p . with an appropriate dilution ofnormal mousebrainhomogenate, were
injected i.p . with 2 gCi of an aqueous solution of ["SIJUDR diluted in 0.5 ml ofMEM . Spleens were
removed 24 h later at which tirhe all retained (' 11IJUDR is associated with cellular DNA (12) . Just
before isotope administration, the activity of several 0.5-ml aliquots was measured in a Packard
Auto-Gamma spectrometer (Packard Instrument Co ., Downers Grove, Ill .) to determine the total
number of radioactive counts being given to each mouse. Since the number of lymphocytes in the
spleen varies after LCM virus infection (13) the results were expressed as the percent of input
[I'llJUDR retained in replicate aliquots of 100 x 10 8 nucleated cells obtained from twice-washed cell
suspensions prepared from the pooled spleens of'a given donorgroup . Thepresence of infectious virus
in these suspensionswas also determined by inoculating0.03-ml aliquots i.c . into groups of ICRmice .
Anti-B Serum.
￿
The procedure used to both prepare and evaluate the specificity of the anti-B
serum used in these studies has been described previously (6, 14) . The method of treating lymphoid
cells with this reagent and guinea pig C is given in detail elsewhere (6) .
Light Microscopy . Mice were perfused with isotonic saline followed by 1% acetic acid in 10%
formalin . Brains were sectioned in paraffin at 8 ym in a parasagittal plane, and stained with
hematoxylin and erythrosin .
Immunofuorescent Staining .
￿
The indirect method wasused employing antiserum to LCM virus
obtained from neonatally inoculated virus-carrier mice 2 wk after their receiving immune lymphoid
cells as adults (7), and a fluoresceinated goat antimouse IgG (Meloy, Springfield, Va .) .
Results
Generation of Virus-Specific Cytotoxic Lymphocytes . Spleen donors were
groups of3-4 BALB/c mice which were immunized i .p . with either 30 x 103 or 3
x 10 3 LDso ofLCM virus and then sacrificed at different times after immuniza-
tion . The kinetics of effector cell generation were essentially identicalusing either
virus dose . The amounts of isotope released by uninfected targets after exposure
to either normal or immune lymphocytes were the same .
As shown in Fig. 1, in the spleens of mice given 30 x 10 3LDSO of'virus, specific
cytolytic activity increased from a barely detectable level on day 4 postinfection
to a maximum of 25-30% on day 8. For the next 2-3 days this ef'f'ector activity
remained relatively unchanged but, thereafter, it gradually decreased to a
threshold level of about 3% by day 30 postinfection . As first suggested by our
earlier but more limited studies (7), the lytic activity of immune lymphoid cellsin r
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FIG. 1 . Generation of cytolytic activity against LCM virus-infected BALB 3T3 cells in
spleens of adult BALB/c mice after i.p . infectionwith 30 x 10'LD so ofLCMvirus . Each point
is the mean percent specific lysis (four experiments) t the standard error.
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obtained at any time during this period was abolished by treatment with anti-B
serum and C .
Spleen Cell Division after LCM Virus Infection.
￿
The kinetics of ['111]UDR
uptake by spleen cells of BALB/c mice immunized with a single dose ofLCM
virus varied little from one experiment to the next (Fig . 2) . A sharp, transient
radioactive peak was regularly observed 7 days after immunization with either of
the two virus doses employed . Correspondingly, the total number of nucleated
cells in day 8 immune spleens had increased between two- and threefold when
compared to cell numbers in spleens from mice given an appropriate dilution of
normal brain .
Two interesting observations can be made from comparing the data in Figs . 1
and 2 . First, maximal cell division in the spleens of infected mice preceded the
time when peak cytolytic activity in this organ was reached and, second, the
observed decrease in cell division appeared to occur more rapidly than the
subsequent fall in effector cell activity . Undoubtedly related to the decline in
both isotope retention and effector cell activity was the disappearance of
detectable infectious virus from the spleens of immunized animals, occurring
regularly between the 8th and 9th days .870
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Although not shown in Fig. 2, this same pattern ofDNA synthesis was also seen
in the spleens of C3H x C57BL F, mice, after primary LCM virus immunization .
Furthermore, i.p. inoculations with virus rendered noninfectious either by
heating at 56°C for 1 h or by a 15 min exposure to ultraviolet light results in levels
of splenic DNA synthesis which were not significantly different from those
obtained after the inoculation of diluted uninfected brain.
J
J
W
U
0.15
w
W
I
0-
U)
0
X
O
O
w
z
a
w
0
w
U
W
d
0.18
0.01
I
￿
I
￿
I
￿
I
￿
1
￿
I
3 4 5 6 7 8
DAYS POSTINFECTION
389)
c31o)
FIG. 2.
￿
DNA synthetic response as measured by ["'IJUDR uptake in spleens of adult
BALB/c mice after i.p. infection with LCM virus: ("), 30 x 103 LDso; ("), 3 x 103 LD56; and
(A), normal mouse brain. Each point is the mean percent isotope retained (three experiments)
24 hafter asingle i.p. 2 pCipulse f the standard error. In parentheses are the average numbers
of nucleated cells per spleen x 106.
Production of Disease in CY-Induced Virus-Carrier Mice. In order to
correlate the ability of immune lymphocytes to lyse cultures of virus-infected
target cells in vitro with their ability to mediate fatal acute CNS disease in
CY-induced virus carriers, groups of adult BALB/c donor mice were immunized
i.p. with either a single dose or four weekly dose of 3 x 103 LD56 of virus. At
selected times after immunization, aliquots containing 100 x 106 viable
nucleated pooled donor spleen cells were adoptively transferred to recipient
virus-carrier mice and also assayed for lytic activity in vitro.
As shown in Table I, 100 x 106nonimmune donorlymphocytes, or lymphocytes
obtained between 6 and 10 days after primary immunization, were largelyEUGENE D. JOHNSON AND GERALD A. COLE
TABLE I
Production of Acute CNS Disease in CY-Induced LCM Virus-Carrier
Mice with Adoptively Transferred Immune Splenic Lymphocytes*
*Adult BALB/c mice inoculated i.c. with virus, given CY 3 days later, and
subsequently adoptively immunized with spleen cells from nonimmune or
immune donors.
t Proportion of mice developing fatal CNS disease during a 14 day observation
period. Mortality between 1* + 10 and 1° + 18 significant at P < 0.025 (X2,
5.32).
§Spleen cells from immune donors were obtained 6, 8, 10, 18, and 30 days after
one i.p. virus dose or 6 and 18 days after the last of four weekly doses. The
percentages of specific cytotoxicity are the same as shown in Fig. 1.
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ineffective in mediating fatal disease even though it was during this same period
that the immune cells exhibited maximum cytotoxicity in vitro. All surviving
mice remained virus carriers, as determined by immunofluorescent staining of
their brains, and none showed any histologic evidence of choriomeningitis.
However, at 18 and 30 days and even up to 90 days (not shown) when their
cytotoxic capabilities were either diminishing or had disappeared, donor splenic
lymphocytes were able to produce fatal choriomeningitis in almost all virus-car-
rier recipients.
The disease-producing ability of lymphocytes from mice given multiple
injections of LCM was markedly greater than lymphocytes from singly immu-
Donor
lymphocytes
Cell dose
(x 108)
Cytoxicity
in vitro
Disease
D/Tt
production
Mortality
Nonimmune 100 0 0/15 0
1* + 6§ 100 20 t 3 1/6 17
10 0/6 0
1'+8 100 28 t 3 1/7 14
1'+10 100 29 t 3 1/6 17
10 0/6 0
1° + 18 100 13 t 2 5/6 83
10 0/6 0
1° + 30 100 3 t 1 6/6 100
4° + 6 100 12 f 3 6/6 100
10 5/6 83
4° + 18 100 3 :±:2 6/6 100
10 5/6 83
4° + 18 (after 100 0/6 0
anti-B + C)872
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nized animals and appeared to be independent ofwhen the cells were obtained
after the last immunizing virus injection. Transfers of either 100 x 106or 10 x 106
lymphocytes produced fatal disease in practically all carrier mice and pretreat-
ment of these cells with anti-O serum and C ablated their ability to mediate
disease . Of interest in these and similar experiments were the consistently lower
levels of cytolytic activity in spleens obtained at various intervals after multiple
immunization as compared with levels present at corresponding times after
primary immunization .
Protection of Susceptible Mice From Lethal LCM.
￿
Since the cytolytically
active spleen cell population generated during at least the first 10 days after
primary immunization with LCM virus was unable to effect a change in the
course ofan established carrier infection, it was of interest to determine whether
this population could prevent or alter the initiation of infection . Accordingly,
spleen cells from nonimmune donors and those obtained at various times after
primary infection were transferred i .p . to groups of normal syngeneic recipients
at a dose containing 100 x 10 6 viable nucleated cells . After an 18-24 h interval,
the recipients were challenged i.c . with 50-100 LDso ofLCM virus and thereafter
observed daily for signs of CNS disease over a 2 wk period .
As shown in Table 11, cytolytically active donor spleen cell populations
obtained only at 6 and 8 days postimmunization were able to significantly
prevent the clinical expression ofLCM . Cells obtained at 4 days and at 10 days
conferred no protection to recipients despite the fact that the latter population
exhibited a degree of cytolytic activity in vitro which was comparable to that of
cells which did protect . The protective capacity of day 8 immune cells was
TABLE II
Protection of Mice Against Lethal LCM With Adoptively Transferred
Immune Splenic Lymphocytes*
Protection
*Adult BALWc mice challenged i.e . with LCM virus 24 h after adoptive
immunization with nonimmune spleen cells or cells obtained from donors 4, 6,
8, 10, and 30 days after primary immunizing infection .
fProportion of animals surviving at 14 days after virus challenge .
§ Mean number of days before death of nonprotected mice .
Donor
lymphocytes
(100 X 10 8 )
Cytotoxicity
in vitro
S/T$ Survival
Mean
survival
times§
% days
Nonimmune 0 0/30 0 8.5
1°+4 3t1 0/8 0 8.0
1'+6 20 t 3 9/15 60 7 .0
1° + 8 28 t 3 22/31 71 7 .0
1° + 8 (after 0 2/9 22 7.0
anti-8 + C)
1'+ 10 29 t 3 0/14 0 8.0
1' ,+ 30 3 t 1 0/15 0 6.0EUGENE D . JOHNSON AND GERALD A. COLE
￿
873
markedly reduced after treatment with anti-B serum and C. In addition,
lymphocytes obtained 30 days after primary immunization, and having barely
detectable cytolytic activity, failed to prevent LCM and also hastened disease
onset.
From additional observations (Table III), it appeared that protection against
fatal disease required that there be a certain minimum interval between spleen
cell transfer and virus challenge. Both day 6 and day 8 immune lymphocytes
failed to significantly protect recipients when given 1 h before challenge.
More direct evidence bearing on the mechanism by which day 8 immune cells
protect mice against LCM was obtained by histologically examining brains from
TABLE III
Protective Ability of Immune Lymphoid Cells Adoptively Transferred
at 1 or 24 h before Virus Challenge*
*Adult BALB/c mice challenged i.e . with LCM virus either 1 or 24 h after
adoptive immunization with spleen cells from immune or nonimmune donors.
f Proportion of animals surviving at 14 days after virus challenge.
these animals as well as measuring their virus content. Two groups of 14 mice
were each given either nonimmune or day 8 immune spleen cells followed by i.c.
virus challenge (50-100 LDsa) 24 h later. On the 6th day of infection, when virus
levels inthe brains ofnonimmunes were maximal (1), a comparison of individual
brain virus titers in five mice from each group revealed approximately 100-fold
less virus in the brains of animals given immune cells (Table IV). Although
histological choriomeningitis was present in all animals, it was generally less
severe in the group which had received immune cells. After 6 days, 100% of mice
which were recipients of nonimmune lymphocytes before virus challenge had
already developed the typical convulsive diathesis preceding fatal LCM,
whereas, only about 30% of immune spleen cell recipients showed some overt
evidence of mild disease. Brains from surviving animals in this latter group were
free of infectious virus.
It should be noted that nosignificant contribution to the protective capacity of
Donor
lymphocytes
(100 x 10)
Time of
challenge
Protection
S/Tt Survival
h %
1° + 6 1 0/5 0
24 4/5 80
1° + 8 1 1/14 7
24 5/5 100
1'+ 10 1 0/5 0
24 0/5 0
Nonimmune 1 0/5 0
24 0/5 0874
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TABLE IV
Reduction of Brain Virus Titers Mediated by day 8 Immune Splenic
Lymphocytes*
Donor
lymphocytes
(100 x 108 )
1 ° +8
Nonimmune
*Adult BALB/c mice challenged i .c . with LCM virus 24 h after adoptive
immunization with spleen cells from day 8 immune or nonimmune donors .
tLogo LD,a/0.03 g brain (mice killed 6 days after challenge) .
§ Proportion of remaining mice which survived challenge .
day 6 or day 8 immune spleen cells could be accounted for by infectious virus (1-2
logs) present at these times in the spleens of donor mice . In preliminary
experiments, similar or greater i.p . viral inocula given to normal mice 1 day
before i.c . virus challenge did not prevent their developing uniformly fatalLCM .
Prevention of Virus-Carrier State Induction in AT x BM Mice . The i .c .
inoculation of LCM virus into adult mice which have been depleted of T
lymphocytes by neonatal thymectomy (15) or by repeated administration of
heterologous antilymphoid sera (16), usually produces neither clinical nor
histological evidence of LCM but, instead, leads to the establishment of the
chronic virus-carrier state . Similarly, congenitally athymic mice (G . A . Cole and
R. A . Prendergast, unpublished observations) or mice thymectomized as adults,
then lethally irradiated and reconstituted with syngeneic bone marrow (17), al-
most invariably develop persistent infections after i.c . virus challenge .
In order to assess the ability ofday 8 immune donor lymphocytes to prevent or
abort the initiation of a persistent LCM virus infection in recipients possessing
little or no endogenous T lymphocytes, groups of C3H x C57BL F, AT x BM
mice were injected i .p . with either 100 x 106 normal or immune splenic
lymphocytes 24 h before i.c . challenge with 50-100 LDSO of LCM virus . For
comparison, AT x BM mice given no lymphoid cells and their unmanipulated
normal littermates were also challenged . During the following 18 days, all mice
developing convulsive disease were killed and their brains examined both
histologically and by immunofluorescent staining . At the end of this period the
remaining mice were treated in the same fashion . The various outcomes are
presented in Table V .
As anticipated, AT x BM mice given virus not preceded by lymphoid cells all
developed an asymptomatic carrier infection with immunofluorescent viral
antigen readily visualized in their neural membranes, and with a total lack of
inflammatory cells at these sites . The administration of nonimmune donor
lymphocyte before virus challenge led to the production of clinical disease in
Brain virus titers*
Protection
S/T§ Survival
2.0, 2.3, 2.4, 3 .6, 4.8 6/9 67
(mean = 3.0)
4.5, 5.0,5.1, 5.3, 5.5 0/9 0
(mean = 5.1)EUGENE D. JOHNSON AND GERALD A. COLE
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TABLE V
Prevention of Virus-Carrier State Induction in AT x BM Mice with
Adoptively Transferred day 8 Immune Splenic Lymphocytes*
* C3H x C57BL F, mice given either lymphoid cells or no cells 24 h before virus
challenge .
$ Symptomatic mice were killed at time of disease onset ; asymptomatic mice
were killed 18 days after challenge .
100% of mice between 8 and 10 days postinfection . Brains from all such animals
showed convincing microscopic evidence of mild to moderate choriomeningitis as
well as viral persistence. In contrast, none of the AT x BM mice given virus
preceded by day 8 immune donor lymphocytes developed overt disease nor was
immunofluorescent viral antigen detectable in neural membranes . However,
histologically, all presented with a mild choriomeningitis indicating that the
transferred immune cells were not only able to mediate some degree of
immunopathology but that they were also capable of preventing the establish-
ment of the virus-carrier state, apparently without the cooperative benefit of
recipient T lymphocytes. All normal littermates developed clinical LCMon the
7th or 8th day postinfection accompanied by a characteristic moderate to severe
choriomeningitis and virus-specific immunofluorescence in cells of the meninges
and choroid plexus .
Discussion
The present data have confirmed our earlier evidence (9, 10) for the existence of
at least two different virus-specific T-lymphocyte subsets generated at different
times in the spleens of mice after immunizing infections withLCM virus . These
subsets are identified by differences in their functional capabilities both in vitro
and in vivo . Lymphocyte populations obtained between 6 and 8 days postinfec-
tion possess high levels of cytolytic activity as measured in vitro and, when
transferred to syngeneic nonimmune normal and AT x BM mice prevent,
respectively, the development of actute lethal CNS disease and the establish-
ment of the virus-carrier state when these animals are challenged i .c . withLCM
virus 18-24 h later . In both situations, CNS infection is transient and virus
appears to be cleared as the direct result of the transferred cells. However, these
cells will elicit neither clinical nor histological evidence of immune-mediated
CNS disease in CY-induced virus-carrier mice . Lymphocytes obtained 18 days
after primary infection, at a time when cytolytic activity is diminished, or at 30
days when it is practically nil, have no protective effect but, instead, actually
Recipients
Donor
lymphocytes
(100 x 10 8 )
Clinical
CNS disease
Histologi-
cal chorio-
meningitis$
Immuno-
fluorescent
viral
antigen$
AT xBM None 0/15 - +
AT xBM Nonimmune 6/6 + +
AT xBM 1° + 8 0/6 + -
Normal None 10/10 + +876
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hasten disease onset when administered to normal mice before virus challenge .
Moreover, these cells regularly produce fatal LCM when transferred to virus-car-
rier mice .
The generation of each of these functionally different T-lymphocyte popula-
tions, hereafter referred to as either effector or memory subsets, bears a definite
temporal relationship to the periods after immunizing infection when virus
initially replicates in visceral tissues and then is subsequently cleared . Thus,
effector activity reaches maximal levels 1 or 2 days before infectious virus in the
spleen becomes undetectable, after which it gradually diminishes . In contrast,
the development of a virus-specific memory subset, as defined by its disease-pro-
ducing potential in virus carriers, occurs well after virus clearance and then
persists for months .
An important observation made during these studies is that the protective role
played by day 6 or day 8 immune lymphocytes cannot be explained simply on the
basis of their effector activity as measured in vitro . Although these cells and day
10 cells have similar levels of activity, only the former are able to prevent the
establishment of CNS infection . What appears to be the determining factor is
whether or not the effector subset is obtained during the time when viral
antigen-induced DNA synthesis is taking place in donor spleens . It could be
argued, therefore, that under the conditions of our experiments, it is a cell
population comprised of the immediate precursors of the effector subset which, in
vivo, actually mediates both the inflammation of neural membranes and the
elimination of virus . The failure of day 10 effector lymphocytes to perform
similarly may be due to their lack of this proliferative component, thereby
restricting their capacity to expand with sufficient rapidity to engage in the
elimination of an increasing number of virus-infected cells . Alternatively,
differences in the in vivo migratory patterns between effector lymphocytes and
their progenitors may influence their respective efficiencies in homing to sites of
antigen (18) which, in this study, is represented by virus in the CNS . Zinkernagel
and Doherty (19) have shown that LCM virus-specific effector T lymphocytes
accumulate in the cerebrospinal fluid of lethally infected mice just before death .
However, it is not clear as to whether the majority of these cells arise after
differentiation locally or whether they migrate to the CNS after being generated
in distant lymphoid tissues .
The inability of day 6 and day 8 immune lymphocytes to protect normal mice if
administered 1 h before virus challenge (Table III) suggests that the donated cells require
some critical period of time to reach either relevant CNS sites or peripheral lymphoid
tissues where cooperation with endogenous lymphoid elements may occur . If some early
cooperative event is indeed necessary for the expression of donor cell protective function, it
apparently does not require the participation of recipient T lymphocytes since protection
occurs in AT x BM mice . The same can be said for the ability of a memory subset to elicit
fatal choriomeningitis in virus-carrier AT x BM mice (G . A . Cole and R . A . Prendergast,
unpublished observations) . The question still remains as to which cell type(s) mediates
cytopathology and virus clearance in vivo . However, it is becoming increasingly evident
from several recent in vitro studies (20, 21) that although the lysis of cultured
virus-infected target cells can be attributed solely to T lymphocytes, the elimination of
virus from the cultures is macrophage dependent . Furthermore, careful electron micro-EUGENE D. JOHNSON AND GERALD A. COLE
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scopic examination of brains from mice (F . A . Murphy, personal communication) and
rats2 during acute LCM virus-induced CNS disease has revealed little if any direct
interaction between virus-containing cells and lymphocytes although macrophages are
abundant . We would therefore favor the notion that, while the hypothetical "kiss of
death" by the effector lymphocyte may be a reality in vivo, the resolution of the infectious
process is accomplished by recruited macrophages . This position is defended in greater
detail by Blanden in a recent review (22) .
Our data do not permit any conclusive statement as to whether or not the early
appearing proliferating cell population derives from the same pool of antigen-reactive
precursors which eventually differentiate into either the effector or the memory subset .
Obviously, the precursors of both subsets must arise during a circumscribed period ofviral
replication . Since the full expression of memory probably occurs about a week after peak
effector activity is reached, it is tempting to speculate that the development of memory
begins when virus falls to levels insufficient to drive a common antigen-reactive precursor
to its more (and perhaps final) differentiated state, i .e ., the effector lymphocyte .
Supporting this idea is the observation that, in comparison with primary immunizing
LCM virus infection, reinfection leads to a marked restriction in viral replication (5) and
to reduced and more transient levels of effector activity (Table 1) . Nevertheless, spleens
from reinfected donor mice show an increased memory potential as reflected by the fewer
number of cells required to elicit CNS disease in virus carriers .
We have emphasized that the various outcomes ofLCM virus infections can be
explained on the basis of the kinetic relationships between viral replication and
immune induction (23) . The present study supports this view . The protection
afforded a normal mouse by a proliferating effector subset does not come from
preventing the initiation of infection in its CNS but is, instead, the result of a
more efficient elimination of virus and/or infected cells after infection is
established . In comparison, the lack of protection by a memory subset could be
attributed to its less differentiated state and therefore a longer period would be
required for the development of effector activity . The accelerated death resulting
from the transfer of a memory subset to normal mice may actually represent the
"too little-too late" expression of this activity .
A totally different set of conditions exists in virus-carrier recipients . These
animals are given immune donor lymphocytes at a time when virus in the CNS
has already reached maximal levels, and the infection has spread to extraneural
tissues resulting in a persistent viremia (1) . Under these circumstances, it is not
surprising that only a memory subset, with its inherently greater potential for
proliferation and differentiation, can alter the course of infection, especially since
these cells, or their progeny, must travel a virus-laden course to the CNS .
Some of the findings presented in this report are supported in related studies by other
workers in this field who used different strains of mice and/or virus . Thus, a carefully
documented study by Hannover Larsen (24) provided strong evidence for the increasing
ability of donor lymphoid cells, obtained at successive intervals after primary LCM virus
infection, to permanently reduce viremia when transferred to syngeneic C3H adult mice
with carrier states induced by neonatal infection . For reasons discussed elsewhere (3, 23),
these animals, unlike CY-induced carrier mice, are insusceptible to the CNS disease-pro-
ducing capacity of immune lymphocytes so that reduction of circulating virus probably
2 Del Cerro, M . and A . A . Monjan . Manuscript in preparation .878
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represents the analogue of immune-mediated CNS disease occurring at extraneural tissue
sites .
Using CBA mice, a significant antiviral effect was noted by Mims and Blanden (25)
when animals were transfused with day 8 immune donor spleen cells 48 h after an i.e . or
i.p . challenge with the viscerotropic WE3 strain ofLCM virus . Under these conditions, no
protective effect was demonstrated but virus titers in the liver and spleen were reduced
about 100-fold 24 h after cell transfer when compared to titers in these organs from
recipients given nonimmune cells . The antiviral effect was almost completely eliminated
if the immune cells were pretreated with anti-B serum . Interestingly, levels of virus in the
brain were unaffected and it is likely that the donated cells were unable to traverse a
gradient of viral antigen favoring extraneural tissues . The transfer of lymphocytes
obtained from donors 95 days after primary infection resulted in no diminution of virus,
suggesting that some differentiating step may have been required before these cells could
exert any antiviral activity .
In basic agreement with our results are those of a recent study by Volkert et al . (26) who
showed that a radioresistant, cytolytically active "early" immune cell population,
obtained from C3H donors 9 days after infection with another viscerotropic virus strain
(Traub), protected normal mice from fatal LCM if transferred at the time of virus
challenge or 2 days after infection . In confirmation of Hannover Larsen's findings (24),
these same cells had little ability to affect the viremia present in adult mice with carrier
infections initiated shortly after birth . "Late" immune cells, obtained 30 days postimmu-
nization, were not protective but were capable of reducing viremia in carrier mice . This
capability was considerably reduced if the cells were X irradiated or treated with anti-B
serum and C before transfer . The demonstrable protective effect of "early" immune cells
given as late as 2 days postinfection, and the relative resistance of these cells to X
irradiation in vitro are observations which appear to be at variance with our interpretation
that the conditions for protection require the transfer of a proliferating effector subset
before the initiation of infection . However, the lymphocyte populations used in these
investigations consisted of both spleen and lymph node cells obtained from donors
immunized with a strain of virus which persists for long periods in visceral tissues (27) .
These variables and possibly others based on genetically controlled differences in the
immunologic reactivity of different mouse strains to LCM virus (28) may have influenced
a particular experimental result .
Employing somewhat different experimental conditions, Doherty and Zinkernagel (29)
have recently demonstrated that cytolytically active splenic T lymphocytes obtained
between 7 and 9 days postinfection of donors with the WE 3 strain of LCM virus could
dramatically shorten the interval to fatal CNS disease in recipient mice previously
inoculated i .e . with the neurotropic Armstrong strain and immunosuppressed with CY .
The donor cells were transfused at a time when the infection was well established in the
neural membranes of recipients but before any extensive invasion of their extranueral
tissues . Under these circumstances the recipients developed a precocious LCM which
appeared as early as 3 days after immune cell transfer, in striking comparison to the 8- to
10-day period preceding the death of animals which received nonimmune cells . Lending
further support to our findings, these investigators found that the transfer of donor spleen
cells taken 11 and 13 days after infection gave the same results as nonimmune cells .
Collectively, the experimental results discussed above illustrate a marked
functional heterogeneity of virus-specific T-lymphocyte subsets generated at
different times afterLCM virus infection . The precise nature of their interaction
with infected cells in vivo, leading to viral clearance and/or immunopathology, is
still unclear . It appears likely that both of these outcomes are mediated by anSummary
At varying intervals after immunizing infections of adult BALB/c mice with
lymphocytic choriomeningitis (LCM) virus, splenic lymphocytes were tested for
their ability to either elicit acute LCM or protect against lethal intracerebral
LCM virus challenge when transferred to syngeneic recipients that were,
respectively, virus carriers induced by cyclophosphamide-induced immunosup-
pression and normal susceptible mice . These lymphocytes were also assayed for
their capacity to lyse, in vitro, LCM virus-infected BALB 3T3 cells labeled with
5'Cr .
Only lymphocytes obtained from donor mice between 6 and 8 days postimmu-
nization significantly protected normal recipients from the development of lethal
central nervous system (CNS) disease when transferred 18-24 h before virus
challenge . At 10 days they were not protective even though their cytolytic
activity in vitro either exceeded or approximated that of protective lymphocytes.
The capacity to protect more closely corresponded with a period of virus-induced
DNA synthesis in donor spleens as measured by the incorporation of [5-' 251 1-2'-
deoxyuridine . However, none of these cytolytically active lymphocyte popula-
tions were effective in mediating acute CNS disease when transferred to
virus-carrier mice . In contrast, lymphocytes obtained 18 days or later after
primary immunization, although having no protective capacity and exhibiting
minimal cytolytic activity in vitro, were able to regularly produce acute disease
in virus-carrier mice . The ablation by anti-B serum treatment of these in vivo and
in vitro virus-specific immune functions established that the relevant lymphoid
cells wereT lymphocytes .
Similarly, reconstitution of C3H x C57BL F, adult mice, depleted of
lymphocytes by thymectomy and lethal irradiation, with syngeneic day 8
immune donor lymphocytes rendered them resistant to the development of the
carrier state after intracerebral virus challenge; reconstitution of such animals
with nonimmune lymphocytes restored their ability to develop typical LCM .
Collectively, these data indicate that immunogenic stimulation with LCM
virus leads to the development of at least two different virus-specific T-lym-
phocyte subsets : (a) an early appearing transient effector population of cells and,
perhaps, their immediate precursors whose generation requires the presence of
virus, and (b) a stable memory population that appears well after virus clearance
and which has little or not no cytolytic activity . The possible mechanism by
which these functionally different subsets can influence the outcome of acute or
chronic LCM virus infections is discussed .
Receiued for publication 6 January 1975 .
EUGENE D . JOHNSON AND GERALD A. COLE
￿
879
effector subset arising from precursor cells in varying stages of viral antigen-
driven differentiation, and in combination with macrophages.
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